Age-related alterations in cyclic nucleotide phosphodiesterase activity in dystrophic mouse leg muscle

Canadian Journal of Physiology and Pharmacology

Volumn 83, Issue 11, 2005, Pages 1055-1060

  Bloom, Timothy J ^a  

^a Campbell University   (United States)

Author keywords

Cyclic nucleotide phosphodiesterase; EHNA; Mouse; Muscular dystrophy; RO 20 1724

Indexed keywords

4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; CYCLIC AMP; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; ERYTHRO 9 (2 HYDROXYL 3 NONYL) ADENINE; PHOSPHODIESTERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG SENSITIVITY; DUCHENNE MUSCULAR DYSTROPHY; ENZYME ACTIVITY; GENETIC REGULATION; LEG MUSCLE; MOUSE; MUSCULAR DYSTROPHY; NONHUMAN; PRIORITY JOURNAL;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; AGING; ANIMALS; FEMALE; HINDLIMB; MALE; MICE; MICE, INBRED MDX; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; PHOSPHODIESTERASE INHIBITORS;

EID: 33644906161     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/y05-085     Document Type: Conference Paper

References (25)

1. Bloom, T.J. 2002. Cyclic nucleotide phosphodiesterase isozymes expressed in mouse skeletal muscle. Can. J. Physiol. Pharmacol. 80: 1132-1135.
2. Bloom, T.J., and Beavo, J.A. 1996. Identification and tissue-specific expression of PDE7 phosphodiesterase splice variants. Proc. Natl. Acad. Sci. U.S.A. 93: 14188-14192.
3. Bulfield, G., Siller, W.G., Wight, P.A.L., and Moore, K.J. 1984. X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc. Natl. Acad. Sci. U.S.A. 81(4): 1189-1192.
4. Canal, N., Cerri, C., Musch, B., and Frattola, L. 1977. Metabolism of cyclic nucleotides in healthy and diseased human muscle. Isr. J. Med. Sci. 13: 147-151.
5. Canal, N., Frattola, L., and Smirne, S. 1975. The metabolism of cyclic-3′-5′-adenosine monophosphate (cAMP) in diseased muscle. J. Neurol. 208: 259-265.
6. Chang, W.J., Iannaccone, S.T., Lau, K.S., Masters, B.S., McCabe, T.J., McMillan, K., Padre, R.C., Spencer, M.J., Tidball, J.G., and Stull, J.T. 1996. Neuronal nitric oxide synthase and dystrophin-deficient muscular dystrophy. Proc. Natl. Acad. Sci. U.S.A. 93: 9142-9147.
7. Cullen, M.J., and Jaros, E. 1988. Ultrastructure of the skeletal muscle in the X chromosome-linked dystrophic (mdx) mouse. Comparison with Duchenne muscular dystrophy. Acta Neuropathol. (Berl.) 77: 69-81.
8. Dangain, J., and Vrbova, G. 1984. Muscle development in mdx mutant mice. Muscle Nerve, 7: 700-704.
9. Harrow, J.A., Singh, J.N., Jasmin, G., and Dhalla, N.S. 1975. Studies on adenylate cyclase-cyclic AMP system of the myopathic hamster (UM-X7.1) skeletal and cardiac muscles. Can. J. Biochem. 53: 1122-1127.
10. Hoffman, E.P. 2001. Dystrophinopathies. In Disorders of voluntary muscle. Edited by G. Karpati, D. Hilton-Jones, and R.C. Griggs. Cambridge University Press, Cambridge, UK. pp. 187-215.
11. Lau, K.S., Grange, R.W., Chang, W.J., Kamm, K.E., Sarelius, I., and Stull, J.T. 1998. Skeletal muscle contractions stimulate cGMP formation and attenuate vascular smooth muscle myosin phosphorylation via nitric oxide. FEBS Lett. 431: 71-74.
12. Mishra, S., KMenon, N.K., Roman, D., and Kumar, S. 1992. Calcium, calmodulin and 3′,5′-cyclic nucleotide phosphodiesterase activity in human muscular disorders. J. Neurosci. 109: 215-218.
13. Movsesian, M.A., and Alharethi, R. 2002. Inhibitors of cyclic nucleotide phosphodiesterase PDE3 as adjunct therapy for dilated cardiomyopathy. Expert Opin. Investig. Drugs, 11: 1529-1536.
14. Netherton, S.J., Jimmo, S.L., Palmer, D., Tilley, D.G., Dunkerley, H.A., Raymond, D.R., Russell, J.C., Absher, P.M., Sage, E.H., Vernon R.B., and Maurice, D.H. 2002. Altered phosphodiesterase 3-mediated cAMP hydrolysis contributes to a hypermotile phenotype in obese JCR: LA-cp rat aortic vascular smooth muscle cells: implications for diabetes-associated cardiovascular disease. Diabetes, 51: 1194-1200.
15. O'Donnell, J.M., and Zhang, J.T. 2004. Antidepressant effects of inhibitors of cAMP phosphodiesterase (PDE4).Trends Pharmacol. Sci. 25: 158-163.
16. Pastoret, C., and Sebille, A. 1995. mdx mice show progressive weakness and muscle deterioration with age. J. Neurol. Sci. 129: 97-105.
17. 2-adernergic receptors by beta arrestin. Science (Washington, D.C.), 298: 834-836.
18. Reddy, Y.S., Reddy, N.B., Mobley, B.A., and Beesley, R.C. 1992. Myofibrillar and membrane-bound enzymes in skeletal muscle from myodystrophic mice. Int. J. Biochem. 24: 579-584.
19. Rodan, G.A., Rodan, S.B., Raible, D.G., Cutler, L.S., Wacholtz, M., and Sha'afi, R.I. 1979. Adenylate cyclase in muscular dystrophy. Ann. N.Y. Acad. Sci. 317: 670-691.
20. Rosen, R.C., and Kostis, J.B. 2003. Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am. J. Cardiol. 92: 9M-18M.
21. Schudt, C., Dent, G., and Rabe, K.F. (Editors). 1996. Phosphodiesterase inhibitors. Academic Press, NY.
22. Sicinski, P., Geng, Y., Ryder-Cook, A.S., Barnard, E.A., Darlinson, M.G., and Barnard, P.J. 1989. The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science (Washington, D.C), 244: 1578-1580.
23. Williams, R.H., and Thompson, W.J. 1973. Effect of age upon guanyl cyclase, adenyl cyclase, and cyclic nucleotide phosphodiesterases in rats. Proc. Soc. Exp. Biol. Med. 143: 382-387.
24. Yarwood, S.J., Steele, M.R., Scotland, G., Houslay, M.D., and Bolger, G.B. 1999. The RACK1 signaling scaffold protein selectively interacts with the cAMP-specific phosphodiesterase PDE4D5 isoform. J. Biol. Chem. 274: 14909-14917.
25. Zeman, R.J., Peng, H., Danon, M.J., Etlinger, J.D. 2000. Clenbuterol reduces degeneration of exercised or aged dystrophic (mdx) muscle. Muscle Nerve, 23: 521-528.